Hydroxy Ivabradine | CAS 1235547-07-5 - Request Quote
Hydroxy Ivabradine
| SZ CAT No: | SZ-I014037 |
| CAS No | 1235547-07-5 |
| Mol.F. | C15H21NO4 |
| Mol.Wt. | 279.3 |
| Inv. Status | Under Synthesis |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
Hydroxy Ivabradine is chemically 3-(3-Hydroxypropyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-2H-benzo[d]azepin-2-one. Hydroxy Ivabradine is supplied with detailed characterization data compliant with regulatory guideline. Hydroxy Ivabradine can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Ivabradine.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
Buy 1235547-07-5
Purchase 1235547-07-5
Order 1235547-07-5
Enquire 1235547-07-5
price of 1235547-07-5
1235547-07-5 Supplier
1235547-07-5 Manufacturer
1235547-07-5 Exporter
buy high quality Hydroxy Ivabradine
Purchase Hydroxy Ivabradine
Hydroxy Ivabradine suppliers
Hydroxy Ivabradine manufacturers
Hydroxy Ivabradine price
Order Hydroxy Ivabradine
Enquire Hydroxy Ivabradine
Hydroxy Ivabradine cost
Hydroxy Ivabradine Supplier
Hydroxy Ivabradine Distributor
Hydroxy Ivabradine for Method Validation
Ivabradine Reference Standard
Hydroxy Ivabradine for ANDA Filing
Hydroxy Ivabradine for Forced Degradation Studies
Hydroxy Ivabradine Identification Standards
Hydroxy Ivabradine for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.


